Applied Genetic Technologies - Stock Price History | AGTC

Historical daily share price chart and data for Applied Genetic Technologies since 2021 adjusted for splits. The latest closing stock price for Applied Genetic Technologies as of September 23, 2021 is 3.42.
  • The all-time high Applied Genetic Technologies stock closing price was 31.69 on June 18, 2014.
  • The Applied Genetic Technologies 52-week high stock price is 9.67, which is 182.7% above the current share price.
  • The Applied Genetic Technologies 52-week low stock price is 3.12, which is 8.8% below the current share price.
  • The average Applied Genetic Technologies stock price for the last 52 weeks is 4.48.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Applied Genetic Technologies Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 5.0558 4.1500 9.8600 2.3600 4.0900 -9.51%
2019 3.5906 2.6500 4.9200 2.5900 4.5200 81.53%
2018 4.7701 3.7500 7.3500 2.2800 2.4900 -30.83%
2017 5.4397 9.5500 10.0500 3.4000 3.6000 -61.50%
2016 13.1903 19.8000 19.8300 6.3500 9.3500 -54.17%
2015 18.3363 21.3100 24.9800 12.0000 20.4000 -2.95%
2014 18.6405 14.7600 31.6900 11.3200 21.0200 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.142B $0.002B
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71